473 related articles for article (PubMed ID: 29048579)
1. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab.
Tsukamoto S; Righi A; Vanel D; Honoki K; Donati DM; Errani C
Jpn J Clin Oncol; 2017 Nov; 47(11):1090-1096. PubMed ID: 29048579
[TBL] [Abstract][Full Text] [Related]
2. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
[TBL] [Abstract][Full Text] [Related]
3. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
4. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
Chinder PS; Hindiskere S; Doddarangappa S; Pal U
Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
[TBL] [Abstract][Full Text] [Related]
6. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
[TBL] [Abstract][Full Text] [Related]
7. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
8. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
[TBL] [Abstract][Full Text] [Related]
9. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
Urakawa H; Yonemoto T; Matsumoto S; Takagi T; Asanuma K; Watanuki M; Takemoto A; Naka N; Matsumoto Y; Kawai A; Kunisada T; Kubo T; Emori M; Hiraga H; Hatano H; Tsukushi S; Nishida Y; Akisue T; Morii T; Takahashi M; Nagano A; Yoshikawa H; Sato K; Kawano M; Hiraoka K; Tanaka K; Iwamoto Y; Ozaki T
World J Surg Oncol; 2018 Aug; 16(1):160. PubMed ID: 30089488
[TBL] [Abstract][Full Text] [Related]
12. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
13. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.
Hasenfratz M; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Roitman PD; Aponte-Tinao LA; Lehner B; Möller P; Mechtersheimer G; Barth TFE
Sci Rep; 2021 Mar; 11(1):5709. PubMed ID: 33707617
[TBL] [Abstract][Full Text] [Related]
14. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
15. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
[TBL] [Abstract][Full Text] [Related]
16. Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report.
Park A; Cipriano CA; Hill K; Kyriakos M; McDonald DJ
JBJS Case Connect; 2016; 6(3):e78. PubMed ID: 29252655
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
[TBL] [Abstract][Full Text] [Related]
19. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
20. A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab.
Aponte-Tinao LA; Piuzzi NS; Roitman P; Farfalli GL
Clin Orthop Relat Res; 2015 Sep; 473(9):3050-5. PubMed ID: 25758379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
